![]() |
||
|
We are a Vancouver, BC based biotech firm and an emerging leader in the discovery and development of new drugs for the treatment of infectious diseases.
Upstream Biosciences designs new drugs, and repurposes existing drugs, using novel computational chemistry pattern matching techniques to treat antibiotic-resistant infectious diseases and cancer. Our innovative approach to drug discovery uses a proprietary artificial intelligence software platform to rapidly and cost effectively generate and optimize drug candidates by leveraging historic test data. Upstream’s process produces a continuous stream of drug candidates and has demonstrated a one in four success rate compared to the pharmaceutical industry average of one in 10,000. Our technology has already generated novel drug candidates that, in preclinical laboratory studies and animal studies, demonstrate both human and veterinary potential against major tropical parasitic diseases. Testing of lead compounds have demonstrated in vitro efficacy and in vivo safety against such diseases as Malaria, African Sleeping Sickness, Nagana and Leishmaniasis. While our initial focus has been on neglected tropical diseases, we believe our proprietary methodology could be applied to a diverse range of illnesses with potential for success. These include various chemotherapy drugs and anti-biowarfare agents (cryptosporidium), drug-resistant tuberculosis and HIV. We have filed over seven provisional patents with regards to our technologies. It is our plan to continue to protect our Intellectual Property through a combination of trade secret and provisional patents, prior to filing Initial Patent Applications with the USPTO and throughout the Patent Cooperation Treaty (PCT) territories. We plan to file our Initial Patent Applications on drug composition and process once our lead drug candidates have been internally selected to go into Clinical Trials.
|
RECENT NEWS Aug. 10, 2009 July 24, 2009 Oct. 7, 2008
|